Harvard Bioscience (HBIO) Cost of Revenue (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cost of Revenue data on file, last reported at $8.5 million in Q1 2026.

• Quarterly Cost of Revenue fell 11.25% year-over-year to $8.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$17.6 million (down 142.29% YoY) and the FY2025 annual result came in at $729000.0, down 98.15% from the prior year.
• Cost of Revenue rose to $8.5 million in Q1 2026 per HBIO's latest filing, from -$26.3 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $24.1 million in Q4 2023 and bottomed at -$26.3 million in Q4 2025.
• The 5-year median for Cost of Revenue is $9.4 million (2024), against an average of $7.6 million.
• The widest annual swing landed in 2022, when Cost of Revenue surged 133.96%; it then plunged 216.83% in 2025.
• Tracing HBIO's Cost of Revenue over 5 years: stood at $12.6 million in 2022, then jumped by 91.04% to $24.1 million in 2023, then retreated by 6.27% to $22.6 million in 2024, then sank by 216.83% to -$26.3 million in 2025, then surged by 132.3% to $8.5 million in 2026.
• Per Business Quant, the three latest HBIO Cost of Revenue figures stand at $8.5 million (Q1 2026), -$26.3 million (Q4 2025), and $48000.0 (Q3 2025).

Peer Comparison